Dopamine D2 receptors and their role in atypical antipsychotic action:: Still necessary and may even be sufficient

被引:309
作者
Kapur, S
Remington, G
机构
[1] Univ Toronto, Schizophrenia Program, Toronto, ON, Canada
[2] Univ Toronto, Ctr Addict & Mental Hlth, PET Ctr, Toronto, ON, Canada
[3] Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A8, Canada
关键词
dopamine; schizophrenia; antipsychotics; atypical;
D O I
10.1016/S0006-3223(01)01251-3
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Atypical antipsychotics are associated with a much lower propensity for extrapyramidal side effects ant, with some exceptions, a lack of sustained prolactin elevation, The authors propose that a low-affinity and fast dissociation (in molecular terms) from the dopamine D-2 receptor, along with administration of the drug in doses that lead to appropriate levels of dopamine D-2 receptor blockade, are the most important requirements for atypicality. Actions at other receptors (5-HT2, D-4, etc.) may not be necessary to achieve atypicality, and while action at these receptors may hale benefits on symptoms such as mood and cognition, this is as yet to be conclusively proven. Why clozapine is effective in refractory patients is still elusive and efforts to make antipsychotics that are devoid of effects on the dopamine D2 receptors so far hale been unsuccessful. In light of this, the authors provide a heuristic model linking pathophysiology and therapeutics and suggest that the ideal treatment for schizophrenia is unlikely to be single-drug with multireceptor blockade (a sort of one-size-fits-all polypharmacy) but will require several specific and targeted treatment strategies that are titrated to match the variable expression of different dimensions of schizophrenia in each patient. (C) 2001 Society of Biological Psychiatry.
引用
收藏
页码:873 / 883
页数:11
相关论文
共 95 条
[1]  
Abi-Dargham A, 1998, AM J PSYCHIAT, V155, P761
[2]   Differentiation of classical and novel antipsychotics using animal models [J].
Arnt, J ;
Skarsfeldt, T ;
Hyttel, J .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1997, 12 :S9-S17
[3]   Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence [J].
Arnt, J ;
Skarsfeldt, T .
NEUROPSYCHOPHARMACOLOGY, 1998, 18 (02) :63-101
[4]  
BOWDEN CR, 1992, J PHARMACOL EXP THER, V262, P699
[5]   Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method [J].
Breier, A ;
Su, TP ;
Saunders, R ;
Carson, RE ;
Kolachana, BS ;
de Bartolomeis, A ;
Weinberger, DR ;
Weisenfeld, N ;
Malhotra, AK ;
Eckelman, WC ;
Pickar, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (06) :2569-2574
[6]  
Bristow LJ, 1997, TRENDS PHARMACOL SCI, V18, P186, DOI 10.1016/S0165-6147(97)90618-0
[7]   D2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects [J].
Broich, K ;
Grunwald, F ;
Kasper, S ;
Klemm, E ;
Biersack, HJ ;
Moller, HJ .
PHARMACOPSYCHIATRY, 1998, 31 (05) :159-162
[8]  
Buchanan RW, 1998, AM J PSYCHIAT, V155, P751
[9]   Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia:: results of a multicentre, double-blind study (the Amisulpride Study Group) [J].
Carrière, P ;
Bonhomme, D ;
Lempérière, T .
EUROPEAN PSYCHIATRY, 2000, 15 (05) :321-329
[10]   Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response [J].
Conley, RR ;
Tamminga, CA ;
Kelly, DL ;
Richardson, CM .
BIOLOGICAL PSYCHIATRY, 1999, 46 (01) :73-77